Please use this identifier to cite or link to this item:
https://open.uns.ac.rs/handle/123456789/9662
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gedawy, Ahmed | en_US |
dc.contributor.author | Al-Salami, Hani | en_US |
dc.contributor.author | Dass, Crispin R. | en_US |
dc.date.accessioned | 2020-02-05T20:32:19Z | - |
dc.date.available | 2020-02-05T20:32:19Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 1021-9498 | en_US |
dc.identifier.uri | https://open.uns.ac.rs/handle/123456789/9662 | - |
dc.description.abstract | An efficient and simple HPLC method has been developed and validated for the simultaneous determination of gliclazide and metformin hydrochloride in bulk and was applied on marketed metformin and gliclazide products. The mobile phase used for the chromatographic runs consisted of 20 mM ammonium formate buffer (pH 3.5) and acetonitrile (45:55, v/v) The separation was achieved on an Alltima CN (250 mm × 4.6 mm x5μ) column using isocratic mode. Drug peaks were well separated and were detected by a UV detector at 227 nm. The method was linear at the concentration range 1.25-150 μg/ml for gliclazide and 2.5-150 μg/ml for metformin respectively. The method has been validated according to ICH guidelines with respect to system suitability, specificity, precision, accuracy and robustness. Metformin limit of detection (LOD) and limit of quantification (LOQ) were 0.8 μg/ml and 2.45 μg/ml respectively while LOD and LOQ for gliclazide were 0.97 μg/ml and 2.95 μg/ml respectively. | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Journal of food and drug analysis | en_US |
dc.subject | Diabetes | en_US |
dc.subject | Gliclazide | en_US |
dc.subject | HPLC | en_US |
dc.subject | Isocratic | en_US |
dc.subject | Metformin | en_US |
dc.title | Development and validation of a new analytical HPLC method for simultaneous determination of the antidiabetic drugs, metformin and gliclazide | en_US |
dc.type | Journal Article | en_US |
dc.type | Research Support, Non-U.S. Gov't | en_US |
dc.identifier.doi | 10.1016/j.jfda.2018.06.007 | - |
dc.identifier.pmid | 30648585 | - |
dc.identifier.scopus | 2-s2.0-85049828570 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85049828570 | - |
dc.description.version | Published | en_US |
dc.relation.lastpage | 322 | en_US |
dc.relation.firstpage | 315-322 | en_US |
dc.relation.issue | 1 | en_US |
dc.relation.volume | 27 | en_US |
item.grantfulltext | open | - |
item.fulltext | With Fulltext | - |
Appears in Collections: | Naučne i umetničke publikacije |
Files in This Item:
File | Size | Format | |
---|---|---|---|
Food and Drug 2019.pdf | 544.94 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
58
checked on May 10, 2024
Page view(s)
58
Last Week
7
7
Last month
0
0
checked on May 10, 2024
Download(s)
42
checked on May 10, 2024
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.